Engineered immune cells take on Hard-to-Treat kidney cancer
NCT ID NCT07645690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immune cell therapy called CLEAR CAR-T (ET-970) in 30 people with advanced clear cell kidney cancer that has not responded to at least two prior treatments. The therapy uses donor immune cells engineered to target a protein called CD70 on cancer cells. The main goals are to check safety and see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLEAR CAR-T cell injection (ET-970) - an engineered immune cell therapy targeting CD70
- What this could lead to
- If it works, this could point toward a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial (30 people) focused on safety. The therapy may not shrink tumors or could cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, China
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, China
-
Urology Department of Chinese PLA General Hospital
RECRUITINGBeijing, China